Y. Inoue et al., Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide, J UROL, 166(4), 2001, pp. 1508-1513
Purpose: Human prostatic acid phosphatase is a prostate specific differenti
ation antigen. Prostatic acid phosphatase levels increase in the serum of p
atients with prostate cancer and its peptide from positions 299 to 307 (PAP
299-307) is recognized by HLA-A2 restricted cytotoxic T lymphocytes. We in
vestigated whether HIA-A2402 binding prostatic acid phosphatase derived pep
tides induce HLA-A2402 restricted, tumor specific cytotoxic T lymphocytes f
rom the peripheral blood mononuclear cells of patients with prostate cancer
.
Materials and Methods: Peptide binding activity was measured with RMA-S-A*A
2402 cell lines and flow cytometry. Cytotoxic T-lymphocyte activity of the
peripheral blood mononuclear cells of patients with prostate cancer and hea
lthy donors was measured by interferon-gamma and (51) creatinine release as
says. Prostatic acid phosphatase expression in the tumor cell lines at the
messenger RNA and protein levels was investigated by reverse transcriptase-
polymerase chain reaction and immunohistochemical analysis, respectively.
Results: An HIA-A2402 binding, prostatic acid phosphatase derived peptide c
onsisting of the prostatic acid phosphatase amino acid sequence from positi
ons 213 to 221 (PAP 213-221, LYCESVHNF) showed the ability to induce HLA-A2
402 restricted and tumor specific cytotoxic T lymphocytes, which are cytoxi
c to prostatic acid phosphatase positive tumor cells from the peripheral bl
ood mononuclear cells of patients with prostate cancer.
Conclusions: PAP 213-221 may be appropriate as a cancer vaccine for specifi
c immunotherapy in patients with HLA-A2402 positive prostate cancer.